Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Emflaza

Roche Basel Switzerland

Roche pays $1.15bn for Sarepta’s Duchenne gene therapy

Pens another gene therapy deal following takeover of Spark Therapeutics

- PMLiVE

Wave’s challenge to Sarepta in Duchenne falls flat

Shares in the company down more than 50%

- PMLiVE

FDA grants surprise OK to Sarepta’s DMD therapy after earlier rejection

Initially had concerns about infection risks and kidney toxicity

- PMLiVE

Biologic patent exclusivity scrapped in new US trade deal

Drugmakers dealt a blow in latest trade negotiations

- PMLiVE

Solid Bio falls as FDA halts DMD trial over safety concerns

Shares in the biotech dropped dramatically following the announcement

- PMLiVE

NHS leader warns politicians not to ‘weaponise’ the health service

Top exec challenges main parties to provide credible solutions to big issues

- PMLiVE

Aspen to pay millions to NHS following drug pricing investigation

CMA found company colluded to create a monopoly in UK market

- PMLiVE

Sarepta rival NS Pharma files Duchenne drug with FDA

Another blow for Sarepta following FDA rejection earlier this year

It’s the guns, stupid

Gun violence in the US – a public health issue – can be better understood through three points

- PMLiVE

Labour party plans to abolish NHS prescription charges

Comes amid increased focus on drug pricing in the US

- PMLiVE

Envision Pharma Group relocates to support expansion

Office moves in the US prompted by significant growth

Novartis day

Novartis close to US bribery settlement

Company faces huge damages pay out

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links